FUJIY vs SIEGY: Which Is the Better Buy in 2026?
Last updated October 2026
Short answer
SIEGY is the larger of the two ($229.75B market cap): the incumbent the market prices for continued execution (20.61x forward earnings, beta 1.29). FUJIY is the smaller challenger ($25.91B), cheaper on forward earnings (13.54x): more room to run, but more to prove. The real question is which set of drivers you believe, and whether owning one (or both) leaves you over-concentrated.
FUJIY vs SIEGY: the tie-breaker metrics
Same yardstick, side by side (as of October 2026). Valuation lined up like this is most meaningful for two names in the same corner of the market, which these are. Figures are approximate; verify before investing.
| Metric | FUJIY | SIEGY | What it tells you |
|---|---|---|---|
| Market cap | $25.91B | $229.75B | Size. The larger name is the incumbent; the smaller has more room to grow and more to prove. |
| Forward P/E | 13.54 | 20.61 | Valuation on next year's expected earnings, the same yardstick for both. Lower is cheaper for that growth; higher means the market is paying up. |
| Trailing P/E | 15.47 | 25.74 | Valuation on the last 12 months. A big drop from trailing to forward means the market expects earnings to jump, so more growth is already in the price. |
| Beta | 0.39 | 1.29 | Volatility vs the market. Above 1 swings harder than the index; below 1 is steadier. Higher beta means bigger drawdowns to hold through. |
| Price vs 52-week range | 58% of range | 64% of range | Where today's price sits between the 52-week low and high. Near the high is momentum with less margin of safety; near the low is out of favor or a discount, depending on why. |
| Price / book | 1.05 | 3.03 | How much you pay over book value. Very high can signal an asset-light, high-return business or a rich price. |
Reading it: FUJIY is the cheaper of the two on forward earnings, but cheaper is not the same as better. Pair the valuation with growth (how far the forward P/E sits below the trailing P/E) and risk (beta) before you decide.
Before you buy: how FUJIY and SIEGY affect your concentration
The metrics above tell you which is the marginally better business. The bigger risk for most people is not picking the slightly worse stock, it is over-concentrating. FUJIY and SIEGY share themes, so owning both, or adding either to what you already hold, can quietly push a large share of your portfolio into one bet.
This is the part a generic comparison page cannot answer, because it depends on what you own. Connect your brokerage and Walnut shows your real, combined FUJIY and SIEGY exposure, flags overlap with your existing positions, and tells you if adding one would tip you past a concentration you are comfortable with, read-only by default, with your login staying at your broker. Walnut is not an investment adviser.
What does FUJIFILM Holdings (FUJIY) do?
FUJIFILM Holdings is best known for photographic film, but film is now a small slice of a ~¥3.4 trillion revenue company. It runs four segments. Healthcare covers medical imaging systems (X-ray, endoscopy, ultrasound, CT and MRI), life science reagents and, most importantly, Bio CDMO: contract manufacturing of biologic drugs for pharmaceutical customers. Electronics sells photoresists, CMP slurries and other semiconductor process materials, plus display films and data storage tape. Imaging includes the instax instant camera line and the X and GFX series of digital cameras. Business Innovation is the former Fuji Xerox office printing and document services arm. FUJIY is an OTC-traded ADR in which one ADR represents 0.5 of a Tokyo share (ticker 4901), which closed near ¥3,416 in late October 2026.
What does Siemens AG (SIEGY) do?
Siemens AG is one of Europe's largest industrial technology companies, headquartered in Munich. It runs four main businesses: Digital Industries (factory automation hardware such as PLCs and drives, plus industrial software including Xcelerator, Teamcenter, NX and the recently acquired Altair and Dotmatics), Smart Infrastructure (electrical products, grid technology and building systems, a big beneficiary of data center and electrification spending), Mobility (rail vehicles, signaling and rail software), and a roughly 67% stake in Siemens Healthineers, the medical imaging and diagnostics company that Siemens plans to separate. Fiscal years end on September 30, and US investors typically hold the company through the SIEGY sponsored ADR, which trades over the counter in dollars rather than on a US exchange. The company employs roughly 300,000 people, sells in close to 190 countries and generates a large share of revenue outside Germany, with the US and China among its biggest markets.
FUJIY vs SIEGY: how do they differ?
Both fit overlapping themes, but they are not interchangeable. The useful comparison is which set of drivers and risks you want exposure to.
- FUJIY drivers: Bio CDMO scale-up at Holly Springs and Denmark; Semiconductor materials riding AI chip demand.
- SIEGY drivers: Electrification and data center demand at Smart Infrastructure; Industrial software and the Altair and Dotmatics deals.
Which fits which kind of investor
A faster-growing, richer-valued name usually swings harder, so it suits a longer horizon and a higher tolerance for volatility; a steadier, more cash-generative business suits a more conservative or income-minded investor. The honest test is which set of risks you could hold through a drawdown: The largest near-term risk is Bio CDMO execution. For SIEGY, siemens is cyclical at the margin: an industrial slowdown, weaker China demand or a pause in data center spending would hit orders and the premium multiple at the same time.
FUJIY or SIEGY: which should you pick?
Growth-minded investors who believe the theme has years to run tend to accept the richer multiple for more upside; value-minded investors lean toward the cheaper forward earnings and steadier profile. Pick FUJIY if you believe its drivers more; SIEGY if you believe its. Many investors hold both, but since they share themes, that is a concentrated bet, not diversification. Decide deliberately and check overlap. For the full detail, see the FUJIY and SIEGY guides.
FUJIY vs SIEGY: the full fundamentals
FUJIY. Trailing figures combine the fiscal year ended March 2026 with the weaker June 2026 quarter, so trailing net income (~¥260 billion) sits below the full-year guide of ~¥280 billion. On that guide, forward earnings are roughly ¥234 per Tokyo share, or about ¥117 per ADR. The valuation sits between pure-play materials suppliers, which often trade above 20x, and office-equipment peers near 10x, which reflects the conglomerate mix. The stock is near the middle of its 52-week ADR range of ~$8.93 to ~$12.18.
SIEGY. At a Frankfurt share price around €240, Siemens trades at roughly 21 times the midpoint of its raised fiscal 2026 EPS guidance, a premium to its own history and to many diversified industrials but below pure-play electrification and automation names such as Schneider Electric. The SIEGY ADR represents one-half of an ordinary share, so its dollar price is roughly half the euro share price converted at the current exchange rate. Full fiscal 2026 results are due in mid-November 2026. The quarterly cadence matters for ADR holders: results arrive in November, February, May and August, and the ADR typically reacts in the US session following the morning German release.
Headline figures (approximate, October 2026): FUJIY shows adr price ~$10.83 (1 ADR = 0.5 share; Tokyo ~¥3,416), market cap ~$26 billion (~¥4.1 trillion), revenue (ttm) ~¥3.43 trillion (~$21.8 billion), net income (ttm) ~¥260 billion (~$1.65 billion); SIEGY shows revenue (ttm) ~€81 billion, fiscal q3 2026 orders ~€27.9 billion (book-to-bill ~1.34), order backlog ~€132 billion, fy2026 eps pre-ppa guidance ~€11.20 to €11.50.
The bottom line: FUJIY vs SIEGY
FUJIY and SIEGY are related but distinct: same themes, different businesses and risks. Neither wins in the abstract; the right pick is whichever thesis you actually believe, sized so you are not over-concentrated in one theme. Walnut can show your combined FUJIY and SIEGY exposure against your real portfolio. It is not an investment adviser.
Wondering how FUJIY or SIEGY fits the portfolio you already own? Walnut is an AI investing app that connects your brokerage read-only and answers questions like that about your actual holdings: overlap, concentration, and how each position tracks the S&P 500. Compare the best AI portfolio analyzers or see the best AI investing apps in 2026.
Investing in FUJIFILM Holdings with AI
Connect the broker you already use and ask Walnut's AI how FUJIY fits what you actually hold: whether you own it already through a fund, what it would do to your concentration, and how it has tracked the S&P 500. Read-only by default, and you approve anything before it reaches your broker.
FAQ
What is the difference between FUJIY and SIEGY?
+
FUJIFILM Holdings is best known for photographic film, but film is now a small slice of a ~¥3.4 trillion revenue company. Siemens AG is one of Europe's largest industrial technology companies, headquartered in Munich. They show up together because they share investment themes, but they are different businesses, so the better fit depends on which thesis you are expressing.
Is FUJIY or SIEGY the better stock?
+
Neither is universally better. SIEGY is the larger incumbent; FUJIY is the smaller challenger and looks cheaper on forward earnings. Walnut is informational, not investment advice. Compare what each does, the tie-breaker metrics above, and the risks, then decide which fits your thesis and what you already own.
Which is cheaper, FUJIY or SIEGY?
+
On forward P/E (as of October 2026), FUJIY trades at 13.54x and SIEGY at 20.61x, so FUJIY is the cheaper of the two on next year's expected earnings. A lower multiple is not automatically the better buy: a richer valuation can be justified by faster growth, and a lower one can reflect real risk. Weigh the multiple against how fast each business is compounding.
Should you own both FUJIY and SIEGY?
+
Because they share themes, owning both concentrates you in that theme. That can be intentional (a focused bet) or accidental (less diversification than it looks). Walnut can show your combined exposure across both, and whether adding either over-concentrates you, before you buy.
What are the risks of FUJIY vs SIEGY?
+
FUJIY: The largest near-term risk is Bio CDMO execution. Regulatory inspection pauses at US plants and delayed profitability at Holly Springs already forced a ~¥28 billion cut to the Healthcare profit target, and further FDA observations, customer program cancellations or slower utilization would extend losses on a very large fixed-cost base. Electronics is cyclical and tied to chipmakers' capex and inventory swings, so a semiconductor downturn would hit the segment currently carrying the group. Currency is a two-way risk for ADR holders: a weaker yen flatters reported yen profits but lowers the dollar value of each ADR, while a sharp yen rally would reverse recent translation gains. US tariffs and higher raw material and energy costs (management flagged Middle East tensions) pressure margins. Business Innovation is a structurally declining office-print market, and a spin-off could disappoint. Finally, FUJIY trades over the counter with thinner liquidity and wider spreads than the Tokyo line, and dividends are paid in yen, converted, and may face Japanese withholding tax. SIEGY: Siemens is cyclical at the margin: an industrial slowdown, weaker China demand or a pause in data center spending would hit orders and the premium multiple at the same time. Software acquisitions carry integration and goodwill risk, and Mobility has a history of lumpy, lower-margin contracts. Tariffs and trade friction between the US, EU and China affect a company with factories and customers in all three. For SIEGY holders specifically, the ADR is priced in dollars but the business reports in euros, so a stronger dollar can reduce returns even if the underlying shares rise, and German withholding tax on dividends (with depositary fees) reduces the net payout. As an OTC ADR, SIEGY can also have wider spreads and thinner trading than the Frankfurt listing, and corporate actions such as the Healthineers distribution may be handled differently for ADR holders (for example sold for cash) than for ordinary shareholders. Finally, the stock has re-rated on record orders, so a quarter of slower bookings could weigh on the shares more than on the fundamentals.
Walnut is informational, not investment advice. This page is descriptive and not a recommendation to buy or sell FUJIY or SIEGY; figures are approximate and dated (as of October 2026). Verify current data before investing.